trial
as of 2026-07-01Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCTId NCT00130923
at a glance
Phase 4 · Completed
Enrollment 95 (actual)
Sponsored by Dartmouth-Hitchcock Medical Center
Primary completion 2009-06
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
95 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2005-09
Primary completion
2009-06
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Dartmouth-Hitchcock Medical CenterLead Sponsor
Investigators
1
Alan I. Green, MDPrincipal Investigator
Sites
8 total
Miami, United StatesKansas City, United StatesSt Louis, United StatesLebanon, United StatesManchester, United StatesNashua, United StatesColumbia, United StatesWhite River Junction, United States
Facts & assertions
4 sourced
Enrollment
95
Phase
PHASE4
Primary Completion Date
2009-06
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person